Peruvian economic watchdog INDECOPI has issued fines on five major drug store chains, having determined their involvement in a price-fixing scheme affecting 36 major medications, violating competition legislation and adversely affecting consumers.
Charges were presented against the Arcangel (Albis SA), Fasa (Farmacias Peruanas SA), Inkafarma (Eckerd Perú SA), Mifarma (Mifarma SA) and Felicidad (Nortfarma SAC) drug store chains, with fines totalling approximately $2,641,992 USD for their involvement in actions classed as ‘anticompetitive’ by Peru’s antitrust legislation.
As well as the economic sanctions mentioned, INDECOPI’s Commission for the Defense of Free Competition (CLC) has ordered the companies to design and implement a three-year program to avoid any relapse into uncompetitive behavior, including special training for sales personnel.
Full Content: Kaos en la Red
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
CVS Health Explores Potential Breakup Amid Investor Pressure: Report
Oct 3, 2024 by
CPI
DirecTV Acquires Dish TV, Creating 20 Million-Subscriber Powerhouse
Oct 3, 2024 by
CPI
South Korea Fines Kakao Mobility $54.8 Million for Anti-Competitive Practices
Oct 3, 2024 by
CPI
Google Offers Settlement in India’s Antitrust Case Regarding Smart TVs
Oct 3, 2024 by
CPI
Attorney Challenges NCAA’s $2.78 Billion Settlement in Landmark Antitrust Cases
Oct 3, 2024 by
nhoch@pymnts.com
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh